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Abstract
Background: Anti-malarial drug resistance poses a threat to current global efforts towards control and elimination
of malaria. Several methods are used in monitoring anti-malarial drug resistance. Molecular markers such as single
nucleotide polymorphism (SNP) for example are increasingly being used to identify genetic mutations related to
anti-malarial drug resistance. Several methods are currently being used in analysis of SNP associated with anti-
malarial drug resistance and although each one of these methods has unique strengths and shortcoming, there is
still need to improve and/or develop new methods that will close the gap found in the current methods.
Methods: TaqMan Allelic Discrimination assays for detection of SNPs associated with anti-malarial drug resistance
were designed for analysis on Applied Biosystems PCR platform. These assays were designed by submitting SNP
sequences associated with anti-malarial drug resistance to Applied Biosystems website. Eleven SNPs associated with
resistance to anti-malarial drugs were selected and tested. The performance of each SNP assay was tested by
creating plasmid DNAs carrying codons of interests and analysing them for analysis. To test the sensitivity and
specificity of each SNP assay, 12 clinical samples were sequenced at codons of interest and used in the analysis.
Plasmid DNAs were used to establish the Limit of Detection (LoD) for each assay.
Results: Data from genetic profiles of the Plasmodium falciparum laboratory strains and sequence data from 12
clinical samples was used as the reference method with which the performance of the SNP assays were compared
to. The sensitivity and specificity of each SNP assay was establish at 100%. LoD for each assay was established at 2
GE, equivalent to less than 1 parasite/μL. SNP assays performed well in detecting mixed infection and analysis of
clinical samples.
Conclusion: TaqMan Allelic Discrimination assay provides a good alternative tool in detection of SNPs associated
with anti-malarial drug.
Background
Spread and emergence of old and new drug resistant para-
sites is threatening malaria control programmes in most
malaria endemic regions [1,2]. Advances that have been
made thus far will only be sustained if monitoring and
reporting of anti-malarial drug resistance becomes an
integral part of malaria control efforts [3]. Anti-malarial
drug resistance and drug efficacy can be monitored by per-
forming therapeutic efficacy studies, measurement of drug
concentrations in blood, in vitro tests that monitor para-
site phenotypic changes and analysis of molecular markers
that monitor genetic changes. Although therapeutic effi-
cacy studies are considered the gold standard method for
determining anti-malarial drug efficacy, each of these
methods presents unique strengths and weaknesses [3-6].
Recent advances in molecular information and technology
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genetic markers as an important alternative method for
detection of drug resistance [7,8].
Plasmodium falciparum manifests its genetic diversity in
several forms: single nucleotide polymorphisms (SNPs),
microsatellite repeats, small insertions or deletions (indels)
and gene duplication. Studies identifying SNPs and gene
duplications associated with anti-malarial drug resistance
have been exploited in evaluation of resistance to treat-
ment [9]. SNPs in one or more genes can be attributed to
cumulative effect of resistance [10,11]. For example, it has
been shown that point mutations in the P. falciparum
dihydrofolate reductase (dhfr) gene at codons A16V, N51I,
C59R, S108N/T and I164L augmented by mutations in the
dihydropteroate synthase (dhps)g e n ea tc o d o n sS 4 3 6 F ,
A437G, K540E, A581G, and A613S/T confer resistance to
sulphadoxine-pyrimethamine [12-14]. Chloroquine resis-
tance is attributed to SNPs in chloroquine resistance
transporter (crt) and/or multidrug resistance gene 1
(mdr1) genes [15-18].
Most of the methods used for detection of drug resis-
tance SNPs are polymerase chain reaction (PCR) based.
Once amplicons are obtained, the presence of SNPs can
be detected by restriction fragment length polymorphisms
(RFLP), DNA sequencing, or single-stranded conformation
polymorphisms [19]. Other methods used for SNP analysis
include single-nucleotide primer extension (SNPE) [20],
melting curve analysis-fluorescence resonance energy
transfer (FRET-MCA) [21], molecular beacons [22], melt-
ing probe hybridization [23], real-time PCR [24] and
microarray [25]. Each of these methods presents unique
advantages and disadvantages. While there is a need to
develop new SNP analysis methods it is important that
next generation SNP analysis improves on the existing
methods. Some desirable qualities for next generation
SNP analysis methods should include improved accuracy
and sensitivity, reduced cost, fast turn-around time, high
through-put capability, and field deployable to mention a
few.
Here, development of TaqMan Allelic Discrimination
assays (SNP assays) for genotyping SNPs associated with
P. falciparum drug resistance performed on Applied Bio-
systems 7500 Fast Real-Time PCR System is described.
The performance of each SNP assay was assessed using
plasmid DNAs which contained PCR fragment carrying
codons of interest from P. falciparum laboratory strains
with known genetic profile. The specificity of the SNP
assays was assessed by comparing SNP assay data to
sequence data of clinical samples.
Methods
Clinical samples
S a m p l e su s e di nt h i ss t u d yw e r eo b t a i n e df r o maP h a s e
IIb paediatric clinical trial conducted between March
2005 and April 2006 at the KEMRI/Walter Reed Project,
Kombewa Clinic in the Kombewa Division of Kisumu
District, Nyanza Province, Western Kenya. The study
was approved by the Ethical Review Committee of the
Kenya Medical Research Institute, Nairobi, Kenya and
Walter Reed Army Institute of Research (WRAIR) Insti-
tute Review Board, Maryland, USA. The details of this
study have been described elsewhere [26]. Genomic DNA
from the clinical sample was extracted from whole blood
using the QIAamp DNA Blood Mini Kit (Qiagen, Vale-
nica CA, USA) as recommended by the manufacturer.
Plasmodium falciparum laboratory strain samples
Genomic DNA from three P. falciparum laboratory strains
was used in this study. Genomic DNA from 3D7 and 7G8
strains was extracted from cultures grown at WRAIR
using QIAamp DNA Blood Mini Kit. K1strain genomic
DNA was obtained from Malaria Reagent Repository
Resource http://mr4.org, MR4.
SNP selection and assay design
Thirty SNP sequences (~100 nucleotides on the left frank
and ~100 nucleotides on the right frank of the allele of
interest) associated with anti-malarial drug resistance were
submitted to Applied Biosystems (AB) website for analysis
of their suitability to be used in SNP assays. After submit-
ting sequences to the custom TaqMan assay design tool
on the AB website, twenty five sequences returned SNP
assays that were considered to be good candidate designs.
The following SNP assays were selected for further analy-
sis: pfdhfr codons A16V, S22N, N51I, C59R, S108N, and
I164L; pfmdr1 codons N86Y, Y184F, S1034C and
N1042D; and pfdhps codon A581G. TaqMan-MGB geno-
typing assay mix for each of these assays was ordered from
AB. Each of these TaqMan-MGB genotyping assay mix
contained a forward and reverse primer, one probe that
perfectly matched to the wild-type sequence variant
labeled with VIC and the second probe matched to the
mutant (SNP) sequence variant labeled with 6-carboxy-
fluorescein (FAM) (Table 1). Probes contained a non-
fluorescent quencher and a minor groove binder moiety
(MGB) which allows for shorter probe sequences to be
designed. TaqMan-MGB genotyping assay mixes were
supplied at 40X concentration.
SNP assay
A working master mix was prepared that contained 0.25 μL
of TaqMan-MGB genotyping assay mix (20X), 2.5 μLT a q -
Man Genotyping Master Mix (Applied Biosystems, Carls-
bad CA, USA) and 2.25 μL of water or 1.25 μL water and
1 μL of human genomic DNA at 50 ng. Human genomic
DNA was added in reactions which were ran with plasmid
DNAs as the template. Each reaction contained 5 μLo f
working master mix and up to 2 μL of template DNA.
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mid DNA or genomic DNA. In some experiments, two dif-
ferent plasmid DNAs were used. In such instances, 0.5 μL
or 1 μL of each plasmid DNA was added to the 5 μLo ft h e
working master mix bringing the final volume of the
reaction to 6 or 7 μL. Extensive experiments (to be reported
elsewhere) have been done which show that such differ-
ences in volume and concentration of real-time PCR reac-
tions do not alter assay performance. Plates were loaded
into Applied Biosystems 7500 Fast Real-Time PCR System
Table 1 Primers and probe sequences of the SNP assays
SNP Assay Name Primers/Probes Sequence (5’-3’)
DHFR16 Forward CAAGTCTGCGACGTTTTCGATATTT
Reverse CCTCATTTTTTTTCCCCTCATTTTTGC
Probe1 CCTTACAACATGCACATAT
Probe2 AACCTTACAACATACACATAT
DHFR22 Forward GCGACGTTTTCGATATTTATGCCATA
Reverse TCCTAGACCTCTAAATGTGTAGTTATTAAAAACCT
Probe1 CCCTCATTTTTGCTTTCAA
Probe2 CCCTCATTTTTGTTTTCAA
DHFR51 Forward ACTACACATTTAGAGGTCTAGGAAATAAAGGA
Reverse GTTGTAACTGCACAAAAATATTTCATATCTAGGG
Probe1 CCATGGAAATGTAATACCAT
Probe2 CCATGGAAATGTATTACCAT
DHFR59 Forward CTAGGAAATAAAGGAGTATTACCATGGAAATGT
Reverse CATCTCTTATATTTCAATTTTTCATATTTTGATTCATTCA
Probe1 CCCTCATTTTTGCTTTCAA
Probe2 CCCTCATTTTTGTTTTCAA
DHFR108 Forward ATGTAAATGATATGCCTAATTCTAAAAAATTACAAAATGT
Reverse GACAATATAACATTTATCCTATTGCTTAAAGGT
Probe1 CTTTCCCAGCTTGTTCT
Probe2 CTTTCCCAGTTTGTTCT
DHFR164 Forward ACAAAGTTGAAGATCTAATAGTTTTACTTGGGAAA
Reverse TTAATTTCTTTTCTAAAAATTCTTGATAAACAACG
Probe1 CCCTCATTTTTGCTTTCAA
Probe2 CCCTCATTTTTGTTTTCAA
MDR86 Forward AGGAGGAACATTACCTTTTTTTATATCTGTGT
Reverse ATTGTACTAAACCTATAGATACTAATGATAATATTATAGGAT
Probe1 CATCACCTAAATTCATGTTC
Probe2 CATCACCTAAATACATGTTC
MDR184 Forward GGTACGAAATTTATAACAATTTTTACATATGCCAGTT
Reverse AAAAACGCAAGTAATACATAAAGTCAAACGT
Probe1 CCTTTTTAGGTTTATATATTTG
Probe2 CCTTTTTAGGTTTATTTATTTG
MDR1034 Forward GACAAAAAAGAAGAATTATTGTAAATGCAGCTT
Reverse AGGATCCAAACCAATAGGCAAAACT
Probe1 CTTTGACTGAATCCC
Probe2 TTTGACAGAATCCC
MDR1042 Forward GGATTCAGTCAAAGCGCTCAATTA
Reverse GTACCTCTTTTAATTAAGAAGGATCCAAACCA
Probe1 ATAGGCAAAACTATTAATAAA
Probe2 TAGGCAAAACTATCAATAAA
DHPS581 Forward TTCTTGTATTAAATGGAATACCTCGTTATAGGAT
Reverse TATACATGTATATTTTGTAAGAGTTTAATAGATTGATCATG
Probe1 TTTCTTCGCAAATCC
Probe2 TTTCTTCCCAAATCC
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ing assay experiment following the default standard Allelic
Discrimination genotyping assay protocol. The initial step
of this protocol includes pre-reading of the plate where the
background florescence is recorded followed by AB stan-
dard PCR protocol of 95°C for 10 min, 95°C for 15 sec and
60°C for 1 min, repeating steps 2-3 for 40 cycles. The post-
read step follows after completion of the PCR step where a
post-read is performed. The software analysed the before
and after florescence level and calculates normalized dye
fluorescence (ΔRn) as a function of cycle number for
Allele1 (wild-type) or Allele2 (mutant). Based on this num-
ber (which is a relative number of the possible outcomes),
the software makes an automatic call of either Allele1
(homozygous1/1), Allele2 (homozygous2/2) or heterozy-
gous (1/2). In some instances however, the software does
not make automatic calls and returns a call of undeter-
mined which can be due to low or no change of fluores-
cence. Also, the system requires large enough sample
number in order to make automatic calls (from communi-
cating with AB technical help line, ~fifteen or more sam-
ples are required for the software to make automatic call).
However, in some instances there is no clear explanation
why the software does not make automatic calls but with
proper controls in place, calls can be made manually by
assessing the calculated normalized dye fluorescence (ΔRn)
as a function of cycle number and the cycle threshold (CT)
values.
DNA amplification and cloning PCR fragments into TOPO
TA vector
Primers were designed (using Primer Express 3.0 software)
that amplified amplicons of interest (Table 2). DNA was
amplified from genomic DNA of either P. falciparum
laboratory strain samples or clinical samples. The amplifi-
cation reaction mixture contained 1 × PCR gold buffer
with MgCl2 in a final concentration of 4 mM, 0.2 mM
deoxynucleoside triphosphates, and 0.4 μM of each pri-
mer. Reactions were carried out in 20 μL reactions con-
taining 1 μL genomic DNA and 1 U AmpliTaq Gold DNA
Polymerase with GeneAmp (Applied Biosystems, Carlsbad
CA, USA). Cycling conditions were 95°C for 10 min fol-
lowed by 40 cycles of 95°C for 15s, 52°C for 10s, and 72°C
for 30s. Amplification of the PCR fragments was con-
firmed by running part of the PCR reaction on a 2% agar-
ose gel and staining with ethidium bromide. PCR
fragments were purified using QIAquick PCR purification
kit (Qiagen, Valenica CA, USA) following manufacturer’s
instructions. Purified PCR fragments were cloned into
pCR 2.1-TOPO vector using TOPO TA cloning kit (Invi-
trogen, USA) following manufacturer’s recommendations.
One Shot TOP10 Chemically or Electrocomp competent
cells (Invitrogen, USA) where transformed with cloned
vector following manufacturer’s recommendations. These
reactions were plated out on kanamycin plates and single
colonies were grown in cultures overnight. Plasmid DNAs
were purified from overnight cultures using QIAgen spin
miniprep kit (Qiagen, Valenica CA, USA) following manu-
facturer’s recommendations. Plasmid DNAs were purified
from a minimum of three colonies for each reaction. To
verify if cloning reaction was successful, PCR was per-
formed using 1 μL of plasmid DNA as template and pri-
mers corresponding to those used to amplify the PCR
fragment cloned into the vector. PCR fragments were ana-
lysed on agarose gel, ensuring the correct PCR fragments
were obtained. Clones with correct PCR fragments were
further confirmed by sequencing as described below. The
concentration and purity of purified plasmid DNA was
measured using NanoDrop 2000 (Thermo Fisher Scientific
Inc, USA) following manufacturer’s instructions. All DNA
samples were required to have a 260/280 ratio of between
1.8 and 2.2. Most samples had 260/280 ratio of between
1.88 and 2.0. Plasmid DNA Genomic Equivalence (GE)
was calculated using the following equation:

Xg / µL DNA/

transcript length nucleotide × 660

×6.022×1023 = Y molecule/µL
Sequencing
Bi-directional sequencing was performed either on plas-
mid DNA or directly on PCR fragments obtained from
genomic DNA. DNA amplifications were performed as
described above and PCR fragments purified using QIA-
quick PCR purification kit. BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Carlsbad CA, USA)
was used for bi-directional sequencing following manu-
facturer’s recommendations. Each reaction contained 4
μL of Terminator Ready Reaction Mix, 3.2 pmol primer,
template DNA (plasmid DNA or purified PCR fragment)
in a final volume of 10 μL. M13F or M13R primers which
are part of TOPO TA cloning kit were used for the bi-
directional sequencing of plasmid DNAs whereas forward
or reverse primers used in generation of the PCR frag-
ments were used in sequencing of these amplicons.
Cycling conditions for the BigDye Terminator reaction
was as follows: 96°C for 1 min followed by 25 cycles of
96°C for 10s, 50°C for 5s, and 60°C for 4 min. The pro-
ducts of these reactions were purified using Performa
Spin Columns (EdgeBio, Gaithersburg MD, USA) follow-
ing manufacturer’s recommendation. Electrophoresis of
these samples was performed using 3130XL Genetic
Analyzer (Applied Biosystems, Carlsbad CA, USA) fol-
lowing manufacturer’s recommendation.
Results
SNP assays performance
To analyse the performance of the selected SNP assays,
three P. falciparum strains, 3D7, 7G8 and K1 that differ
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(Table 3) were used to generate plasmid DNAs contain-
ing PCR fragment of genes carrying codons of interest.
Four PCR fragments that contained all the eleven SNPs
were amplified from respective genes and cloned into
TOPO TA vectors as described in the methods section.
Primers used for amplification of these PCR fragments
are shown on table 2. Amplicon sizes were as follows;
the amplicon that carried pfdhfr codons A16V, S22N,
N51I, C59R, S108N, and I164L was 526 bp; the ampli-
con that carried pfmdr1 codons N86Y and Y184F was
735 bp; the amplicon that carried pfmdr1 codons
S1034C and N1042D was 447 bp; and the amplicon that
carried pfdhps codons A581G was 357 bp. Pfdhfr codons
A16V, S22N, N51I, C59R, S108N and I164L PCR frag-
ments were amplified from 3D7 and 7G8 strains. These
fragments were cloned into TOPO TA vectors and the
plasmid DNAs generated are referred to as 16-3D7 and
16-7G8. Plasmid DNA 16-3D7 was used for analysis of
codons A16V, S22N, C59R, and I164L. Note that the
genetic profiles of these codons are the same (wild-type)
in 3D7 and 7G8 strains. Plasmid DNAs 16-3D7 and 16-
7G8 were used for analysis of codons N51I and S108N,
which 3D7 and 7G8 strains have different genetic pro-
files at these codons. For codons pfmdr1 N86Y, Y184,
S1034C, N1042D and pfdhps codon A581G, plasmid
DNAs were generated by cloning PCR fragments from
K1 and 7G8 strains. K1 and 7G8 strains have different
genetic profiles at these codons. The generated plasmid
DNAs are referred to as follows; plasmid DNAs carrying
pfmdr1 codons N86Y or Y184F are referred as 86-K1 or
86-7G8; plasmid DNAs carrying pfmdr1 codons S1034C
and N1042D are referred to as 1034-K1 or 1034-7G8;
and plasmid DNAs carrying pfdhps codon A581G are
referred to as 581-K1 or 581-7G8. The concentration of
each plasmid DNA was determined using NanoDrop
and the genomic equivalence (GE) was calculated. To
obtain the initial analytical sensitivity and specificity,
each plasmid DNA was diluted to an initial final con-
centration of 32, 000 copies. SNP assays were performed
as described in methods section. SNP assay names were
based on the codon being analysed. For example, to ana-
lyse codon pfdhfr N51I, the SNP Assay name is refer-
enced as DHFR51 (Table 1). Performance of each SNP
assay was assessed based on the known genetic profile
of each strain at each codon and sequence data. Assess-
ment of each SNP assay was based on automatic calls,
normalized dye fluorescence (ΔRn) as a function of
cycle number for Allele1 (wild-type) or Allele2 (mutant),
and the CT values. All the calls made (11 of 11) for
each SNP assay were correct, establishing the initial ana-
lytical sensitivity and specificity at 100%. To establish
the Limit of Detection (LoD) for each assay, each plas-
mid DNA was serially diluted 5-fold and the initial ten-
tative LoD for each assay was set as the lowest
concentration of DNA that yielded positive results in
duplicate experiments (Figure 1: shows LoD for pfdhfr
51 and 108, pfmdr1 86 and 184, pfmdr1 1034 and 1042,
pfdhps 581). The LoD was confirmed by testing the LoD
concentration in replicates of two or more. All the
assays had LoD of 2 GE.
Mixed infections
To test the ability of each assay to discriminate mixed
infections, plasmid DNAs carrying alternate genetic pro-
files at each codon were mixed at different ratios and the
ability of each assay to make the correct call was assessed.
SNP assays analysed for mixed infection were DHFR51
and 108 (using plasmid DNA 16-3D7 and 16-7G8),
MDR86 and 184 (using plasmid DNA 86-K1 and 86-7G8),
MDR1034 and 1042 (using plasmid DNA 1034-K1 and
1034-7G8), and DHPS581 (using plasmid DNA 581-K1
Table 2 Primer sequences used in generation of plasmid DNAs.
Plasmid generated Sequence (5’-3’) PCR fragment size
16-3D7/7G8 Forward Primer CAAGTCTGCGACGTTTTCGATATTT
Reverse Primer TTAATTTCTTTTCTAAAAATTCTTGATAAACAACG 526 bp
86-K1/7G8 Forward Primer TGGGTAAAGAGCAGAAAGAGAAA
Reverse Primer TTGCAACAGTTCTTATTCCCATT 735 bp
1034-K1/7G8 Forward Primer CAAGCGGAGTTTTTGCATTT
Reverse Primer TTCCACCATCATCTCTTACATCA 447 bp
581-K1/7G8 Forward Primer TGCATAAAAGAGGAAATCCACA
Reverse Primer TCCAATTGTGTGATTTGTCCA 357 bp
Table 3 Genetic profile of P. falciparum laboratory strains
Codon 16 22 51 59 108 164 86 184 1034 1042 581
Wild-type C G A T G A A A A A C
Mutant TA T CA TTT T G G
3D7 C G A T G A A A A A C
7G8 C G T T A AATTGC
K1 C G N N A A T AA AG
Genetic profile of P. falciparum laboratory strains used in this study based on
PlasmoDB website www.plasmodb.org and/or sequence data. Bold indicates
the mutant allele and N indicates there is no information available on the
profile of the indicated allele on PlasmoDB website.
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as follows; one plasmid DNA concentration was kept con-
stant while the other was serially diluted 5-fold or both
plasmid DNAs were serially diluted 5-fold and mixed at
equal concentrations. As shown in Figure 2 (DHFR108
SNP assay, MDR1034 SNP assay and DHPS581 SNP
assay), when one plasmid DNA concentration was kept
constant (high) while the other was serially diluted, the
presence of heterozygous alleles was only detected when
both plasmid DNAs were at high concentration. The pre-
sence of the allele in the serially diluted plasmid DNA was
not detected beyond when the plasmid DNAs were at
equal concentrations. However, for MDR1034 SNP assay,
both alleles were detected when one plasmid DNA was
diluted to 6400 GE (Figure 2, MDR1034 SNP assay) while
the other was at kept at 32000 GE. Curiously, the software
did not make automatic calls for the DNA mixtures that
contained serially diluted plasmid DNA at 1:5 (6400 GE)
and undiluted plasmid DNA (32000 GE) for DHFR51,
MDR1042 and DHPS581 SNP assays, rendering these six
assays undetermined. There is no clear explanation why
such results were obtained (undetermined) at these plas-
mid DNA mixture ratios since the software made auto-
matic calls for the consequent plasmid DNA mixtures.
Note that the software did not make automatic calls for all
MDR86 and MDR184 SNP assays. Notwithstanding,
Allele1 and Allele2 ΔRn in these SNP assays were clearly
separated but yet the software could not make automatic
calls (Figure 3). Manual calls were made based on ΔRn
values of the Allele1 and Allele2. It was determined the
performance of these two SNP assays, MDR86 and
MDR184 were similar to those of the other SNP assays.
Interestingly, in all the SNP assays, when both plasmid
DNAs were serially diluted, the presence of both alleles
was detected at or near LoD as established using single
plasmid DNA.
Assay specificity
Twelve samples from the clinical trial were randomly
selected and sequenced directly or by cloning PCR
Figure 1 LoD for DHFR51 and DHFR108, MDR86 and MDR184, MDR1034 and MDR1042, DHPS581 SNP assays. Data showing LoD for
allele1 and allele2 for each SNP assay where plasmid DNA carrying either allele1 or allele2 was used as a template. LoD for all the SNP assays
was established at 2 GE. Data is shown indicating the SNP assay and the strain which the PCR fragment in the plasmid DNA was cloned from.
Example 51-3D7 is data obtained from SNP assay DHFR51 using 16-3D7 plasmid DNA.
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the alleles for each SNP assay were used in these experiments by mixing them in a each reaction. Plasmid DNAs were serially diluted 5-fold
starting at 32000 GE down to 2 GE. In some experiments, the concentration of one of the plasmid DNA was kept constant while the other was
serially diluted whereas in other experiments, both plasmid DNAs were serially diluted and mixed at equal DNA concentrations.
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TA vector. Primers used for cloning and/or sequencing
are described in Table 2. Here, similar scheme was used
as that described in the results section, SNP assay per-
formance. PCR fragments were amplified using different
primer sets and amplicons were either cloned into
TOPO TA vector and then sequenced or were directly
sequenced as described in the methods section. SNP
assays were performed in replicates of two or more for
each sample using either cloned plasmid DNA and/or
Figure 3 Manually called SNP assays. Data showing the manual call of MDR86 and MDR184 SNP assays. The automatic call for these SNP
assays during these runs were undetermined however as the data shows, Allele1 and Allele2 ΔRn in these SNP assays were clearly separated.
This data shows manual calls can be made with great confidence regardless of whether automatic calls are made or not. In addition, CT values
showed a clear and distinct difference between the two alleles.
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plasmid DNAs were used as positive controls for each
allele in all the assays analysed. For DHFR16, 22, 59,
and 164 SNP assays, only 16-3D7 plasmid DNA was
used as positive control (Allele1) because at these
genetic loci, both 3D7 and 7G8 strains carry wild-type
alleles. For DHFR51 and 108 SNP assays, 16-3D7 and
16-7G8 plasmid DNAs were used as positive controls
(Allele1 and Allele2 respectively) because at these
genetic loci, 3D7 and 7G8 carry different alleles (Table
3). 86-7G8 and 86-K1 plasmid DNAs were used as
Allele1 and Allele2 positive controls respectively for
MDR86 SNP assays whereas for MDR184 SNP assays,
86-K1 and 86-7G8 plasmid DNAs were used as Allele1
and Allele2 positive control respectively. 1034-K1 and
1034-7G8 plasmid DNAs were used as Allele1 and
Allele2 positive controls for MDR1034 and 1042 SNP
assays respectively. For DHPS581 SNP assay, 581-7G8
and 581-K1 plasmid DNAs were used as Allele1 and
Allele2 positive controls respectively. K1 and 7G8
strains differ at all these genetic loci as shown (Table
3). SNP assays were performed as described in the
methods section. Figure 4 shows an Allelic Discrimina-
tion plots for DHPS581 and MDR86 SNP assays ran
using clinical samples and plasmid DNA controls. The
plot shows a clear and distinct separation between the
two alleles. In these experiments unlike those initially
ran, automatic calls were made for MDR86 and 184
SNPs assays since large number of samples and controls
were used, emphasizing the need of analyzing a large
number of samples for the software to make automatic
call. To assess the analytical specificity of the SNP
assays, calls made using SNP assay data were compared
to the sequence data of the samples. All calls made
using SNP assays were in 100% agreement with
sequence data. Sequence analysis is considered a gold
standard method for SNP analysis. Eleven SNP assays
were analysed in 12 clinical samples, representing a
total of 132 SNP assays that were correctly called. This
analysis, in addition to that initially performed using
3D7, 7G8 and K1 strains represent 100% specificity of
all the SNP assays analysed.
Clinical samples analysis
Sixty clinical samples with known parasite density based
on microscopy and real-time PCR data [27] were ana-
lysed using all the eleven SNP assays. All the SNP assays
performed as expected with distinct and clear calls
regardless of the parasite density in each sample. In
additional, 10 clinical samples that were negative by
microscopy and real-time PCR data were ran for further
analysis of the analytical specificity of the SNP assays.
There were no false positives; all the CT values were
undetermined.
Figure 4 Allelic Discrimination plots for MDR86 and DHPS581 SNP assays. Two representative plots showing performance of two assays in
analysis of clinical samples. These assays show clear separation between the signals derived from allele1 or allele2. Allele1 is shown in red and
allele2 is shown in blue. Lime green represents a mixture of the two alleles (which was a positive control allele1/allele2 derived using a mixture
of two plasmid DNAs).
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A TaqMan Allelic Discrimination assays for detection of
SNPs associated with anti-malarial drug resistance has
been described. The assay was developed for use on
Applied Biosystems 7500 Fast Real-Time PCR System.
The performance of each of the SNP assays was analysed
and control plasmid DNAs developed. Each SNP assay
performed well with 100% sensitivity and specificity. Data
from genetic profiles of the P. falciparum laboratory
strains and sequence data from 12 clinical samples was
used as the reference method with which the SNP assays
were compared to. All the SNP assays had LoD of 2
copies, which is equivalent to less than 1 parasite/μL
(based on unpublished data to be reported elsewhere).
The performance of the SNP assays was further validated
when each SNP assays was used to assess SNP genetic
profile of additional 60 clinical samples with known para-
site density based on microscopy and real-time PCR assay
which amplifies 18s RNA. Based on microscopy, the den-
sity of the parasite ranged from less than a 100 parasites/
μL to more than 10E6 parasites/μL[ 2 7 ] .A l lS N Pa s s a y s
performed well regardless of parasite density. Using real-
time PCR 18s RNA parasite density data, SNP assays suc-
cessfully genotyped samples containing parasites densities
of 10 parasites/μL or less. All clinical samples that were
negative by real-time PCR 18s RNA assay were also nega-
tive in all SNP assays.
Detection of SNPs associated with anti-malarial drugs
using real-time PCR based assay has been extensively
reported [28]. However, until recently [29], there has not
been any published work towards developing SNP detec-
tion assays using the TaqMan Allelic Discrimination assay
method on Applied Biosystems PCR platform for genotyp-
ing SNPs present in the Plasmodium genome. In the study
by Daniel et al., [29], TaqMan Allelic Discrimination assay
was developed for identification and tracking P. falci-
parum. Here, the authors selected a panel of twenty-four
SNPs that were identified to exhibit a high minor allele
frequency for which robust TaqMan genotyping assays
were constructed. A variety of samples including P. falci-
parum laboratory strains, frozen whole blood, or whole
blood spotted onto filter paper were used in the assay with
a success rate > 99%. The performance of the assay was
validated using nested PCR. By making calls using ΔRn,
TaqMan Allelic Discrimination assays simplifies and
increases accuracy in call making by eliminating subjective
decision which can be made by use of CT values. In most
of the mixed infections, data present here show that if
only CT values were used, wrong calls would have been
made. For example in Figure 3 where 1034-K1 plasmid
DNA at 32000 GE was mixed with 1034-7G8 plasmid at
6400 GE, the MDR1034 SNP assay had CT values of 17.53
and 19.25 for Allele1 and Allele2 respectively and ΔRn
values of 2.23 and 2.27 for Allele1 and Allele2 respectively.
Here, heterozygous1/2 automatic call was made but if this
decision was based on CT values, probably subjective call
would have been Allele1. Automatic calls are less subjec-
tive since they are based on the software’s algorithm. It is
important to have positive and negative controls in place
and a large number of samples must be analysed for the
software to make automatic calls.
Currently, there are many methods that are being used
for molecular analysis of anti-malarial drug resistance.
Methods chosen by different studies will be based on
many factors including technology capabilities and avail-
ability, the availability of intellectual and financial
resources to mention a few. Some of the factors that
should be important in decision making regarding what
assay to use in SNP analysis should include accuracy of
the assay, sensitivity, robustness, reproducibility, cost, and
reliability. Here, we are adding one more tool that can be
used in genotyping anti-malarial drug resistance.
TaqMan Allelic Discrimination assays can be custom
designed for detection of SNPs of interest. When design-
ing these assays however, just like any other PCR assay,
not all SNP sequences will be good candidate designs.
And once good candidate designs are identified, it is
important that extensive analysis of each assay is per-
formed before its utilization. It is important that a SNP
detection assay is capable of detecting mixed alleles
(mixed infection). Here, just like previously reported [29],
data shows that TaqMan Allelic Discrimination assay is
capable of detecting mixed alleles. However, it is impor-
tant to note that this is a PCR based assay which discrimi-
nates the presence of either allele based on affinity of one
probe to the SNP sequences of the allele present as
opposed to the one not present. Some SNP assays might
detect mixed infections better than others; it all depends
on chemistry of each set of probes. Data presented here
show that SNP assays can detect mixed infections when
DNA of both alleles is present in high to very low concen-
trations as long as DNAs carrying both alleles are at or
near equal concentration.
Conclusion
The SNP assay described here for detection of anti-
malarial drug resistance is accurate, sensitive, robust,
inexpensive, highly reproducible and reliable. And since
it is a real-time PCR based assay, it has great potential of
being utilized in high-throughput studies such as surveil-
lance and epidemiological studies. TaqMan Allelic Discri-
mination assays have been widely developed and used for
genotyping SNPs in applications such as SNP typing in
forensic genetics, pharmacokinetics and bacterial strain
typing [30]. However, it is not until recently that Daniels
et al [29] showed utilization of this technology in allele
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note however that all real-time PCR based assays will
poorly detect mixed infections where one allele is at
much higher concentration than the other. If there is
need to resolve mixed infection that might have large dif-
ferences in DNA concentration between the two alleles,
other technologies such as nested PCR must be utilized.
To alleviate limitation associated with detecting mixed
infection, TaqMan Allelic Discrimination assay can be
modified by performing nested PCR where flanking pri-
mers can be used in first round to improve the likely
hood of detecting mixed infections during the real-time
PCR second (nested) round.
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